Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Aspergillosis Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Aspergillosis Overview | 11 | 1 |
| Pipeline Products for Aspergillosis Comparative Analysis | 12 | 1 |
| Aspergillosis Therapeutics under Development by Companies | 13 | 2 |
| Aspergillosis Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Aspergillosis Pipeline Products Glance | 16 | 4 |
| Late Stage Products | 16 | 1 |
| Clinical Stage Products | 17 | 1 |
| Early Stage Products | 18 | 1 |
| Unknown Stage Products | 19 | 1 |
| Aspergillosis Products under Development by Companies | 20 | 1 |
| Aspergillosis Products under Investigation by Universities/Institutes | 21 | 1 |
| Aspergillosis Companies Involved in Therapeutics Development | 22 | 19 |
| Amplyx Pharmaceuticals, Inc. | 22 | 1 |
| Astellas Pharma Inc. | 23 | 1 |
| Biomar Microbial Technologies | 24 | 1 |
| Biosergen AS | 25 | 1 |
| Cidara Therapeutics, Inc. | 26 | 1 |
| F2G Ltd | 27 | 1 |
| Hsiri Therapeutics LLC | 28 | 1 |
| iCo Therapeutics Inc. | 29 | 1 |
| Matinas BioPharma Holdings, Inc. | 30 | 1 |
| Merck &Co., Inc. | 31 | 1 |
| Nanomerics Ltd | 32 | 1 |
| Novabiotics Limited | 33 | 1 |
| Pulmatrix, Inc. | 34 | 1 |
| Pulmocide Ltd | 35 | 1 |
| Scynexis, Inc. | 36 | 1 |
| Sealife PHARMA GMBH | 37 | 1 |
| Sigma-Tau S.p.A. | 38 | 1 |
| TGV-Laboratories | 39 | 1 |
| Vical Incorporated | 40 | 1 |
| Aspergillosis Therapeutics Assessment | 41 | 9 |
| Assessment by Monotherapy Products | 41 | 1 |
| Assessment by Target | 42 | 2 |
| Assessment by Mechanism of Action | 44 | 2 |
| Assessment by Route of Administration | 46 | 2 |
| Assessment by Molecule Type | 48 | 2 |
| Drug Profiles | 50 | 44 |
| amphotericin B Drug Profile | 50 | 2 |
| amphotericin B Drug Profile | 52 | 1 |
| amphotericin B Drug Profile | 53 | 3 |
| amphotericin B Drug Profile | 56 | 1 |
| Amphotericin B sodium Drug Profile | 57 | 2 |
| APX-001 Drug Profile | 59 | 2 |
| ASP-9726 Drug Profile | 61 | 1 |
| Aspergillus fumigatus vaccine Drug Profile | 62 | 1 |
| BSG-005 Drug Profile | 63 | 1 |
| C-001 Drug Profile | 64 | 1 |
| C-016 Drug Profile | 65 | 1 |
| celastrol Drug Profile | 66 | 1 |
| Cellullar Immunotherapy for Viral Infections and Fungal Infections Drug Profile | 67 | 1 |
| F-901318 Drug Profile | 68 | 2 |
| itraconazole Drug Profile | 70 | 2 |
| KB-425796C Drug Profile | 72 | 1 |
| MDN-0018 Drug Profile | 73 | 1 |
| Myc-102 Drug Profile | 74 | 1 |
| NP-339 Drug Profile | 75 | 1 |
| NP-525 Drug Profile | 76 | 1 |
| PC-945 Drug Profile | 77 | 1 |
| posaconazole Drug Profile | 78 | 2 |
| PTX-3 Drug Profile | 80 | 1 |
| SCY-078 Drug Profile | 81 | 4 |
| SLP-0901 Drug Profile | 85 | 1 |
| SLP-0904 Drug Profile | 86 | 1 |
| Small Molecule for Aspergillosis Drug Profile | 87 | 1 |
| Small Molecules for Aspergillosis and Candidiasis Drug Profile | 88 | 1 |
| Small Molecules for Fungal Infections Drug Profile | 89 | 1 |
| Small Molecules for Fungal Infections Drug Profile | 90 | 1 |
| Small Molecules for Invasive Aspergillosis Drug Profile | 91 | 1 |
| Vaccine for Fungal Infections Drug Profile | 92 | 1 |
| VL-2397 Drug Profile | 93 | 1 |
| Aspergillosis Dormant Projects | 94 | 1 |
| Aspergillosis Discontinued Products | 95 | 1 |
| Aspergillosis Product Development Milestones | 96 | 11 |
| Featured News &Press Releases | 96 | 1 |
| Oct 26, 2016: F2G Announces Publication of Initial F901318 Data in Scientific Journal PNAS | 96 | 1 |
| Sep 12, 2016: Amplyx Pharmaceuticals Initiates Dosing in Phase 1 Clinical Trial of APX001, a Novel Antifungal Product Candidate for Treatment of Life-Threatening Infections | 96 | 1 |
| Aug 24, 2016: SCYNEXIS Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Aspergillus Infections | 97 | 1 |
| Jun 16, 2016: Antifungal work lands SBU professor $6 million from NIH | 97 | 2 |
| Jun 14, 2016: Amplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections | 99 | 1 |
| May 24, 2016: Amplyx Pharmaceuticals Appoints Paul C. Grint, M.D., to Board of Directors | 100 | 1 |
| Mar 30, 2016: FDA Grants Vical Fast Track Designation for VL-2397 for the Treatment of Invasive Aspergillosis | 100 | 1 |
| Mar 07, 2016: Vical Initiates Phase 1 Trial of Novel Antifungal Compound VL-2397 | 101 | 1 |
| Jan 28, 2016: SCYNEXIS Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections | 101 | 1 |
| Jan 06, 2016: FDA Grants Vical Orphan Drug Designation for VL-2397 for the Treatment of Invasive Aspergillosis | 102 | 1 |
| Dec 17, 2015: Matinas BioPharma s Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Treatment of Aspergillus by U.S. FDA | 103 | 1 |
| Nov 30, 2015: F2G to Participate in the Adaptive Pathways Pilot Programme | 103 | 1 |
| Sep 21, 2015: SCYNEXIS Presents Data Supporting the Potential Clinical Utility of Antifungal Drug Candidate at ICAAC/ICC 2015 | 104 | 1 |
| Sep 15, 2015: Vical to Present Preclinical Data at ICAAC 2015 Meeting for Its Novel Antifungal Drug Candidate VL-2397 | 105 | 1 |
| Aug 19, 2015: FDA Grants Qualified Infectious Disease Product Designation to VL-2397, Vical's Antifungal Product Candidate | 105 | 2 |
| Appendix | 107 | 2 |
| Methodology | 107 | 1 |
| Coverage | 107 | 1 |
| Secondary Research | 107 | 1 |
| Primary Research | 107 | 1 |
| Expert Panel Validation | 107 | 1 |
| Contact Us | 107 | 1 |
| Disclaimer | 108 | 1 |